Merz Pharma Gmbh & Co Kgaa

Ramot at Tel-aviv University Ltd.

Christopher Graham Raphael Parsons

Wojciech Danysz

Valerjans Kauss

Markus Henrich

Ivars Kalvinsh

Aigars Jirgensons

Tanja Weil

Jens Nagel

Maksims Vanejevs

Claudia Jatzke

Markus R Gold

Aleksandrs Gutcaits

Ronalds Zemribo

Ieva Jaunzeme

Andrzej Dekundy

Mirko Hechenberger

Juris Fotins

Hermann Russ

Dina Trifanova

Igors Starchenkovs

Jevgenijs Rozhkovs

Meik Sladek

Angela Bauer

Aleksandra Gutcaits

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of &#x3b2;-amyloid (A&#x3b2;) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.

Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Glycine B antagonist

Substituted pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors

The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Growing community of inventors

Nidderau, Germany

Christopher Graham Raphael Parsons